Treatment options for patients with primary myelofibrosis

Background Primary myelofibrosis (PMF) is a myeloproliferative disorder resulting in progressive bone marrow fibrosis. In some PMF patients, a mutation in the gene coding for janus-associated kinase 2 (JAK2) results in cell proliferation and evasion of apoptosis. PMF typically occurs in older patients, and is associated with poor prognosis and low survival, with death occurring secondary to cardiovascular disease.(1) Investigations include full blood counts, blood film analysis, and bone marrow aspiration and trephine. Treatment is largely palliative; the single curative intervention of stem-cell transplant being available only to low-risk younger patients. Potential supportive treatments include the use of JAK2 inhibitors. Method This case report studies a patient who was diagnosed with PMF at